ChristopherMReynoldsMD

Oncology • Brighton, MI

Hematologist / Oncologist at St. Joseph Mercy Ann Arbor

Join to view full profile

Dr. Reynolds is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Reynolds' full profile

Already have an account?

Office
7575 Grand River Rd
Brighton, MI 48114
Phone+1 810-844-7290

Fax+1 810-844-7295
Is this information wrong?

Education & Training

University of Michigan Health SystemFellowship, Hematology and Medical Oncology, 1995 - 1998
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1992 - 1994
University of MinnesotaInternship, Internal Medicine, 1991 - 1992
Weill Cornell MedicineClass of 1991

Certifications & Licensure

OR State Medical License 2005 - Present
MI State Medical License 1995 - 2026
WA State Medical License 2005 - 2012
MN State Medical License 1994 - 1996
NY State Medical License 1993 - 1994
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction Start of enrollment: 2009 Jan 21
Terminated
Phase 1, Phase 2
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2010 Sep 01
Completed
Phase 1, Phase 2
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
Active, not recruiting
Phase 3
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Start of enrollment: 2011 Feb 09
Completed
Phase 2
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Start of enrollment: 2011 Apr 08
Active, not recruiting
Phase 2
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Start of enrollment: 2011 Oct 01
Completed
Phase 2
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01
Completed
Phase 2
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery Start of enrollment: 2012 Jun 12
Active, not recruiting
Phase 2, Phase 3
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2013 Dec 01
Terminated
Phase 2
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma Start of enrollment: 2013 Oct 01
Completed
Phase 2
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
Active, not recruiting
Phase 3
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
Active, not recruiting
Phase 3
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer Start of enrollment: 2015 Aug 27
Completed
Phase 2
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Nivolumab Plus Ipilimumab in Patients With Solid Tumors WithMutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Rohatgi, N., Rothe, M., Mangat, P., Garrett-Mayer, E., Meric-Bernstam, F., Pisick, E., Alese, O., Reynolds, C., Thota, R., Vaccaro, G., von Mehren, M., Arend, R., Chiu...> ;JCO Precision Oncology. 2023 Sep 1
1 citations
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors WithMutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
Meric-Bernstam, F., Rothe, M., Mangat, P., Garrett-Mayer, E., Gutierrez, R., Ahn, E., Cannon, T., Powell, S., Krauss, J., Reynolds, C., von Mehren, M., Behl, D., Calfa...> ;JCO Precision Oncology. 2023 Sep 1
88 citations
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) wit...
Brian G.M. Durie, Antje Hoering, Rachael Sexton, Muneer H. Abidi, Joshua Epstein, S. Vincent Rajkumar, Angela Dispenzieri, Stephen P. Kahanic, Mohan C. Thakuri, Freder...> ;Blood Cancer Journal. 2020 May 11
58 citations
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a r...
Roy S. Herbst, Mary W. Redman, Edward S. Kim, Thomas J. Semrad, Lyudmila Bazhenova, Gregory A. Masters, Kurt R. Oettel, Perry Guaglianone, Christopher M. Reynolds, Ana...> ;The Lancet. Oncology. 2018 Jan 1
571 citations
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autolo...
Brian G.M. Durie, Antje Hoering, Muneer H. Abidi, S. Vincent Rajkumar, Joshua Epstein, Stephen P. Kahanic, Mohan C. Thakuri, Frederic J. Reu, Christopher M. Reynolds, ...> ;Lancet. 2017 Feb 4
3 citations
Unrelated donor bone marrow transplantation using a chemotherapy-only preparative regimen for adults with high-risk acute myelogenous leukemia.
Lois Ayash, Voravit Ratanatharathorn, Thomas Braun, Samuel M. Silver, C. Reynolds, J. Uberti> ;American Journal of Hematology. 2007 Jan 1
66 citations
Nephrotic syndrome associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Pavan Reddy, K Johnson, Joseph P. Uberti, C. Reynolds, Samuel M. Silver, Lois Ayash, Thomas Braun, Voravit Ratanatharathorn> ;Bone Marrow Transplantation. 2006 Jul 24
68 citations
Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease
J. Uberti, Lois Ayash, Voravit Ratanatharathorn, Samuel M. Silver, C. Reynolds, Michael Becker, Pavan Reddy, Kenneth R. Cooke, Gregory A. Yanik, Joel Whitfield, Dawn J...> ;Biology of Blood and Marrow Transplantation. 2005 Sep 1
17 citations
Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation:...
J. Uberti, Lois Ayash, Thomas Braun, C. Reynolds, Samuel M. Silver, Voravit Ratanatharathorn> ;Bone Marrow Transplantation. 2004 Sep 1
16 citations
Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Laura A. Dawson, Naoyuki G. Saito, Voravit Ratanatharathorn, J. Uberti, Paul T. Adams, Lois Ayash, C. Reynolds, Samuel M. Silver, Matthew J. Schipper, Allen S. Lichter...> ;International Journal of Radiation Oncology, Biology, Physics. 2004 May 1
16 citations
West Nile virus encephalitis causing fatal CNS toxicity after hematopoietic stem cell transplantation.
Pavan Reddy, R Davenport, Voravit Ratanatharathorn, C. Reynolds, Samuel M. Silver, Lois Ayash, James L.M. Ferrara, J. Uberti> ;Bone Marrow Transplantation. 2004 Jan 1
173 citations
Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody
Voravit Ratanatharathorn, Lois Ayash, C. Reynolds, Samuel M. Silver, Pavan Reddy, Michael Becker, James L.M. Ferrara, J. Uberti> ;Biology of Blood and Marrow Transplantation. 2003 Aug 1
1 citations
Clinical protocol. Purging of autologous stem cell sources with bcl-x(s) adenovirus for women undergoing high-dose chemotherapy for stage IV breast carcinoma.
Lois Ayash, Michael F. Clarke, Paul T. Adams, James L.M. Ferrara, Voravit Ratanatharathorn, C. Reynolds, B. Roessler, Samuel M. Silver, Myla Strawderman, J. Uberti, Ma...> ;Human Gene Therapy. 2001 Nov 1
20 citations
Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literatur...
Lois Ayash, Michael F. Clarke, Samuel M. Silver, Thomas Braun, J. Uberti, Voravit Ratanatharathorn, C. Reynolds, James L.M. Ferrara, E. R. Broun, Paul T. Adams> ;Bone Marrow Transplantation. 2001 May 1
31 citations
Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma
C. Reynolds, Voravit Ratanatharathorn, Paul T. Adams, Thomas Braun, Samuel M. Silver, Lois Ayash, Erik Carson, Avraham Eisbruch, Laura A. Dawson, Kevin T. McDonagh, Ja...> ;Bone Marrow Transplantation. 2001 Apr 1
123 citations
Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease
Voravit Ratanatharathorn, Erik Carson, C. Reynolds, Lois Ayash, John E. Levine, Gregory A. Yanik, Samuel M. Silver, James L.M. Ferrara, J. Uberti> ;Annals of Internal Medicine. 2000 Aug 15
Outcomes in breast cancer patients relative to margin status after treatment with breast-conserving surgery and radiation therapy: the University of Pennsylvania exper...
Peterson ME, Schultz DJ, Reynolds C, Solin LJ> ;Int. J. Radiat. Oncol. Biol. Phys.. 1999-03-15
Multimodal approach to screening for ovarian cancer.
Jacobs I, Stabile I, Bridges J, Kemsley P, Reynolds C, Grudzinskas J, Oram D> ;Lancet. 1988-02-06
Join now to see all

Lectures

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) w...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018